We are proud to announce the return of our 5th
annual Orphan Drugs event to London on the 19th -20th October 2016!
The global
orphan drug market totaled nearly $123 billion in 2014 and will continue to grow to reach nearly $191 billion by 2019. With such growth and innovation witnessed in this field now is the best time to discuss and strategize the best route to market.
In the past year (2015) alone, the Food and Drug Administration have approved 21 new entities. The orphan drug market has seen a dramatic increase in pharmacologic cures for rare diseases, such as Gaucher's disease (Cerezyme/Imiglucerase), atypical Hemolytic Uremic Syndrome (Soliris/Eculizumab) and Non-Hodgkin's Lymphoma (Rituxan/Rituximab). Such entities have revolutionized medicine and paved the way for other drug candidates to enter this space.
Our 5th annual
Orphan Drugs event will bring together leading industry professionals to discuss the latest regulatory developments, explore how to reduce costs and learn from the latest innovations in the orphan drug landscape.
Why You Should Attend Orphan Drugs 2016:
- Explore the development of orphan drugs and how they prevent, diagnose and treat rare diseases
- Understand the industry with a focus on emerging markets and partnering with venture capitals
- Discuss the role of patient associations and how they are helping to fund the rare diseases field
- Learn strategies on defending the pricing of orphan products and how to establish a foundation for reimbursement
- Discover a new business model for developing rare diseases treatments
- Panel Discussion: How can multi-stakeholder parnterships improve the orphan drug field
Plus Two Interactive Half-Day Pre-Conference Workshops | Tuesday 18th October 2016
WORKSHOP A: Planning for success: Developing the optimal orphan drug development strategy
08.30 - 12.30
Workshop Leaders: Alex Bloom, Director of Regulatory Affairs, Cell Medica
Diego Ardigo, Project Leader Advanced Therapies, Chiesi Farmaceutici S.p.A.
WORKSHOP B: Paving the way for achieving orphan drug market access
13.30 - 17.30
Workshop Leaders: Ad Rietveld, Director, RJW & Partners
John Spoors, Senior Consultant, RJW & Partners
Speakers
- Aaron Barzey, CEO, ADB Medical
- Ad Rietveld, Ad Rietveld, RJW & partners Ltd
- Alex Bloom, Director of Regulatory Affairs, Cell Medica Ltd
- Anders Waas, Chief Executive Officer, Tikomed
- Cecile De Coster, Associate Director, Regulatory Affairs, Alexion Pharma International SÓrl
- Daniel O'Connor, Medical Assessor, MHRA
- Diana Ribeiro, CEO, Action Duchenne
- Diego Ardigo, ATMP Project and Clinical Program Leader, Chiesi Farmaceutici SpA
- Gulce Belgin, Director, Proceutica
- James Mcarthur, Chief Scientific Officer, Cydan
- Judith Ng-Cashin, Chief Scientific Officer, INC Research
- Michelle Berg, Vice President, Patient Advocacy, Abeona Therapeutics
- Nigel Nicholls, Director and Country Manager UK/Ireland, BioMarin Europe Ltd
- Oliver Timmis, CEO, AKU Society
- Rick Thompson, Scientific Officer, Findacure
- Robert Karl, Partner, RBV Capital
- Sheela Upadhyaya, Associate Director - Highly Specialised Technologies , National Institute for Health and Care Excellence
- Tim Miller, President & CEO, Abeona Therapeutics
- Tim Guilliams, Founder & CEO, Healx
- Tony Hall, Therapeutic Area Head, Orphan Diseases, Mereo BioPharma
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under dwonloads at the right side of the page.
Venue
Holiday Inn Kensington Forum
97 Cromwell Rd, Kensington, SW7 4DN
London, UK
Venue
Holiday Inn Kensington Forum97 Cromwell Road
London, United Kingdom
